Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar and Calcijex for calcium absorption in hemodialysis
NCT00073710Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Mean within subject difference in calcium absorption rates between treatment regimens. Started Sep 2004; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00073710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073710.